Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A combination study of ME-401with Rituxan® in indolent lymphoma & diffuse large B-cell lymphoma (DLBCL)

Trial Profile

A combination study of ME-401with Rituxan® in indolent lymphoma & diffuse large B-cell lymphoma (DLBCL)

Planning
Phase of Trial: Phase II

Latest Information Update: 30 Aug 2018

At a glance

  • Drugs ME 401 (Primary) ; Rituximab (Primary)
  • Indications Diffuse large B cell lymphoma; Lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Aug 2018 According to MEI Pharma media release, company Expecting to initiate this trial by year-end.
    • 15 Nov 2017 New trial record
    • 08 Nov 2017 MEI Pharma Expecting to initiate this trial in the fourth quarter of 2017, as reported in a media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top